While the fee-for-service reimbursement model has long been accepted as the standard model in healthcare, it must shift to one that focuses on value. Value-based reimbursement will encourage stakeholders to achieve the triple aim: improve patient experience, better manage population health, and reduce per-capita costs of healthcare so that patients receive more for the dollar spent, said Dan Sontupe, executive vice president, payer marketing & market access, The Cement Bloc.
While the fee-for-service (FFS) reimbursement model has long been accepted as the standard model in healthcare, it must shift to one that focuses on value. Value-based reimbursement will encourage stakeholders to achieve the triple aim: improve patient experience, better manage population health, and reduce per-capita costs of healthcare so that patients receive more for the dollar spent, said Dan Sontupe, executive vice president, payer marketing & market access, The Cement Bloc.
In the FFS diabetes management world, formulary design focuses on 1 or 2 preferred brands. There is standard contracting, co-pay cards (which are great for patients and annoying for payers), and a one-size-fits-all approach to treatment algorithms. Often patient education was ineffective due to understaffed offices that lacked case managers. Uncoordinated care among providers resulted in 1 in 10 healthcare dollars being spent on treating diabetes. What’s more, without change, 21% of us population projected to have type 2 diabetes.
In a value-based type 2 diabetes management world, care aligns with the evolving value-based healthcare environment. Strategies focus on self -management, team- based collaborative care, and patient-centered care that meets an individual’s goals and needs. It also includes population health registries, proactive case managers and diabetes educations, and there will be open access to all medications.
This new value equation for type 2 diabetes includes better outcomes, lower costs, engaged patients, bundled payments, attainable quality measures, integrated hospital systems, and accountable care. With programs such as the Healthcare Effectiveness Data and Information Set (HEDIS), Physician Quality Reporting System (PQRS), and Medicare 5-star rating program, quality measures will become imperative for any healthcare organization. This is because value-based care calls for new or renewed tactics to reduce costs of care, manage side effects, and support a positive patient experience.
“Obtaining quality measures in type 2 diabetes is all about lowered costs, we can get there…by driving [value-based] programs and solutions,” said Mr Sontupe.
Diabetes is also not the only area of focus for manufacturers and provider. Oncology is also increasingly garnering interest in value-based care. Value-based cancer care means focusing more on just a patient’s survival — Mr Sontupe said it’s about helping them survive with dignity, and knowing when it is no longer worth the cost or pain of administering expensive treatments. He added that organizations will not activate stakeholders or expand their brand unless they implement strategies that build payer belief in their brand — much as Copernicus had to with his model of the universe.
“Just ‘another value proposition’ is not going to cut it. It’s not going to get you where you need to be, it’s not going to get your product where it needs to be. To move your organization you have to think bigger, said Mr Sontoupe.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
How Pharmacy Deserts, Biosimilars, and Market Trends Are Shaping Managed Care
April 2nd 2025Rising biosimilar adoption, shifting market dynamics, and escalating supply chain vulnerabilities are driving change in managed care, creating both challenges and opportunities for stakeholders, as explored by speakers at the Academy of Managed Care Pharmacy’s annual meeting.
Read More
Using AI-Driven Strategies to Optimize Specialty Drug Costs, Manage Polypharmacy
April 2nd 2025As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.
Read More
Areas of Unmet Need Continue to Burden Patients With gMG
April 2nd 2025Patient-reported outcomes measures in generalized myasthenia gravis (gMG) are more important than ever, for both those treating and being treated for the chronic autoimmune neuromuscular disorder, to have a more nuanced understanding of experiences and difficulties.
Read More